ESC 2026: The First Guidelines on Cardiovascular and Kidney Diseases
This Medudy course is a video podcast for physicians on the 2026 ESC guidelines regarding cardiovascular diseases in chronic kidney disease. Prof. Dr. Michael Böhm and Prof. Dr. Norbert Frey explain why a systematic approach to the heart-kidney axis is becoming increasingly crucial for risk assessment, diagnosis, and treatment. The focus is on determining eGFR and albuminuria, as well as identifying […]
ESC 2026: The New Heart Failure Guidelines
with Prof. Dr. Michael Böhm and Prof. Dr. Holger Thiele This Medudy course is a video podcast for physicians on the clinically relevant updates to the 2026 ESC Guidelines on Heart Failure. Prof. Dr. Michael Böhm and Prof. Dr. Holger Thiele discuss the new classification of heart failure, the staging system from A to D, and the revised assessment […]
Glomerulonephritis: Prevalence, Classification, and Treatment
This Medudy course is a video tutorial for physicians on the topic of “Glomerulonephritis: Prevalence, Classification, and Treatment.” Prof. Dr. Jürgen Floege, a nephrologist and senior professor at the Department of Nephrology and Hypertension at Aachen University Hospital, provides a general overview of glomerulonephritis in this video, which is part of a video series focusing on C3 glomerulopathy (C3G). He […]
PNH in Everyday Clinical Practice
This Medudy course is a video tutorial for physicians on the topic of “PNH in Everyday Clinical Practice.” In this video, Dr. Jörg Chromik, senior physician and director of the Outpatient Clinic for Hematology and Oncology at Frankfurt University Hospital, discusses paroxysmal nocturnal hemoglobinuria (PNH) and its significance in everyday clinical practice. In this first video of a series […]
The Urothelial Carcinoma Cohort of the Destiny-PanTumor02 Trial: Efficacy and Safety of Trastuzumab Deruxtecan in Patients with Metastatic HER2-Expressing (IHC 3+) Solid Tumors
This Medudy course is a video tutorial for physicians on the topic “The Urothelial Carcinoma Cohort of the Destiny-PanTumor02 Trial: Efficacy and Safety of Trastuzumab Deruxtecan in Patients with Metastatic HER2-Expressing (IHC 3+) Solid Tumors.” Dr. Niklas Klümper, a senior physician in urology at the University Hospital of Bonn specializing in medical tumor therapy, summarizes the key findings of the […] in this video.
Training Series on Lung Cancer Early Detection Using Low-Dose Computed Tomography (LDCT)
This Medudy video series is a video tutorial for physicians on the topic of “Continuing Education Series on Early Detection of Lung Cancer Using Low-Dose Computed Tomography (LDCT).” As chair of this continuing education series, Prof. Dr. Felix Herth, a pulmonologist and respiratory medicine specialist at the Thoraxklinik Heidelberg, together with his colleagues Prof. Dr. Hans Hoffmann, Dr. Ingrid Dänschel, Prof. Dr. Jens Vogel-Claussen, and Dr. Claudia Bauer-Kemény, presents referral […]
ASCO 2026 Update – Advanced Ovarian Cancer
This Medudy course is a video podcast for physicians on the topic of “Primary vs. Interval Surgery in Advanced Ovarian Cancer.” Prof. Dr. Sven Mahner and Prof. Dr. Fabian Trillsch discuss the role of surgical therapy in advanced ovarian cancer on the sidelines of the American cancer conference ASCO 2026. The focus is on recent analyses of the TRUST study comparing primary […]
Long-Term Management and Adverse Effect Management with Lorlatinib – Weight Gain
This Medudy course is a video tutorial for physicians on the topic of “Long-Term Management and Side Effect Management with Lorlatinib—Weight Gain.” In this video, Dr. Carolin Groß-Ophoff, senior physician in hematology and oncology at the City of Cologne Hospitals, discusses the ALK tyrosine kinase inhibitor lorlatinib, which is approved for the treatment of advanced, ALK-positive non-small cell lung cancer. Due to its […]
Long-Term Management and Adverse Effect Management with Lorlatinib – CNS Effects
This Medudy course is a video tutorial for physicians on the topic of “Long-Term Management and Side Effect Management with Lorlatinib—CNS Effects.” In this video, Dr. Carolin Groß-Ophoff, senior physician in hematology and oncology at the City of Cologne Hospitals, discusses the ALK tyrosine kinase inhibitor lorlatinib, which is approved for the treatment of advanced, ALK-positive non-small cell lung cancer. Due to its […]
PTEN Deficiency in Metastatic Hormone-Sensitive Prostate Cancer: Clinical Relevance and Unmet Medical Needs
This Medudy course is a video tutorial for physicians on the topic “PTEN Deficiency in Metastatic Hormone-Sensitive Prostate Cancer: Clinical Relevance and Unmet Medical Needs.” In this video, Prof. Markus Eckstein of the Institute of Pathology at Erlangen University Hospital discusses the clinical significance of PTEN alterations in metastatic hormone-sensitive prostate cancer (mHSPC). The loss of the tumor suppressor PTEN activates […]